350 related articles for article (PubMed ID: 33779622)
1. Production of Human CRISPR-Engineered CAR-T Cells.
Agarwal S; Wellhausen N; Levine BL; June CH
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33779622
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
4. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
5. Retroviral Vectors for Cancer Gene Therapy.
Schambach A; Morgan M
Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
[TBL] [Abstract][Full Text] [Related]
6. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
7. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Li C; Mei H; Hu Y
Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
[TBL] [Abstract][Full Text] [Related]
8. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
Yang Z; Pietrobon V; Bobbin M; Stefanson O; Yang J; Goswami A; Alphson B; Choi H; Magallanes K; Cai Q; Barrett D; Wang B; Qi LS; Marincola FM
J Transl Med; 2023 Feb; 21(1):158. PubMed ID: 36855120
[TBL] [Abstract][Full Text] [Related]
9. Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts A; Marsh LC; Srivastava AA; Bouffard AA; Boroughs AC; Scarfò I; Larson RC; Bedoya F; Choi BD; Frigault MJ; Bailey SR; Leick MB; Vatsa S; Kann MC; Prew MS; Kleinstiver BP; Joung JK; Maus MV
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900862
[TBL] [Abstract][Full Text] [Related]
10. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
11. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
13. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O; Koski J; Maliniemi P; Ianevski A; Klievink J; Leitner J; Pölönen P; Hohtari H; Saeed K; Hannunen T; Ellonen P; Steinberger P; Kankainen M; Aittokallio T; Keränen MAI; Korhonen M; Mustjoki S
Blood; 2020 Feb; 135(9):597-609. PubMed ID: 31830245
[TBL] [Abstract][Full Text] [Related]
14. Genome-Edited T Cell Therapies.
Ottaviano G; Qasim W
Hematol Oncol Clin North Am; 2022 Aug; 36(4):729-744. PubMed ID: 35773047
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
[TBL] [Abstract][Full Text] [Related]
16. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
Ghaffari S; Khalili N; Rezaei N
J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
[TBL] [Abstract][Full Text] [Related]
18. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
19. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence.
Wei W; Chen ZN; Wang K
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
